Revolutionizing disease management for Alzheimer's through digital
Exploring challenges and opportunities
There are over 5.8 million Alzheimer’s disease patients in the United States in 2020, and cases are expected to triple over the next four decades. This debilitating disease not only affects patients, but also their loved ones.
Digital solutions have the opportunity to lighten the physical and emotional load for patients and their caregivers, so it’s not surprising that disease management and neuroscience both ranked high in our survey of biopharma leaders’ priorities.
In this white paper, we explore the key challenges faced by Alzheimer’s patients, their caregivers and their care teams. Download now to learn more about the opportunities for biopharma companies in this space, including:
- Increasing patient and caregiver engagement
- Improving provider visibility into each patient’s changing condition
- Generating the data required to make a compelling case for reimbursement
Biopharma and R&D